Resources

October 2, 2019
When it comes to ensuring medicines -- including biosimilars -- are safe and effective for patients, the FDA remains the global gold standard.
barriers to biosimilar adoption
September 9, 2019
This white paper will provide an explanation to the perverse mixture of brand-name biologic companies’ anti-competitive market access tactics and inadequate incentives that have cost the U.S. health care system billions of dollars in lost savings.
July 23, 2019
In July of 2018, the U.S. Food and Drug Administration (FDA) released the Biosimilars Action Plan (BAP). At the one year mark, the agency has made significant progress with the BAP, but more can be done to ensure biosimilars are approved as efficiently as possible.
June 26, 2019
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars Council to talk about biosimilars, their benefits and the hurdles to adoption in the United States.
June 25, 2019
The Association for Accessible Medicines (AAM) Biosimilars Council found that delayed entry of biosimilars due to patenting has cost the U.S. health care system an astounding $7.6 billion in lost savings since 2015.
June 25, 2019
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars Council to talk about biosimilars, their benefits and the hurdles to adoption in the United States.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER